Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519271 · ClinicalTrials.gov registry record · Phase 4
Mild Cognitive Impairment in Parkinson's Disease
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01519271: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01519271 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01519271, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease. Even mild cognitive difficulties can lead to worse functioning, quality of life, depression, and difficulty for caregivers. Thus, ideally treatment at this stage would improve both cognitive symptoms and some of the other problems associated with these symptoms. Despite the fact that mild cognitive impairment is a serious problem for Parkinson's disease patients little is known about how best to treat it. This study is a 24-week clinical trial to see if a Food and Drug Administration (FDA)-approved drug, the Exelon (rivastigmine) Patch, is useful in treating mild cognitive impairment in patients with Parkinson's disease. Currently, the Exelon (rivastigmine) Patch is FDA-approved for the treatment of mild to moderate dementia in Alzheimer and Parkinson's disease patients.
Interventions
- DRUG Exelon Patch (rivastigmine transdermal system)
- DRUG Placebo Patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519271
The ClinicalTrials.gov registry entry for NCT01519271 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exelon Patch (rivastigmine transdermal system) is the first listed.
NCT01519271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01519271 about?
NCT01519271 is a clinical study titled "Mild Cognitive Impairment in Parkinson's Disease". Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease. Even mild cognitive difficulties can lead to worse functioning, quality of life, depression, and difficulty for...
What is the current status of trial NCT01519271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-12. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01519271?
The interventions under investigation include: Exelon Patch (rivastigmine transdermal system) (DRUG), Placebo Patches (DRUG).
Who is sponsoring clinical trial NCT01519271?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.